Free Trial
→ Man who predicted $100K Bitcoin sees a huge run coming for another coin … (From Weiss Ratings) (Ad) Buy AURA Stock  Free AURA Stock Alerts

Aura Biosciences (AURA) Financials

Aura Biosciences logo
$5.99 +0.10 (+1.70%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.16 +0.17 (+2.75%)
As of 05/27/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Aura Biosciences

Annual Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -87 -76 -59
Consolidated Net Income / (Loss)		 -87 -76 -59
Net Income / (Loss) Continuing Operations		 -87 -76 -59
Total Pre-Tax Income 		-87 -76 -59
Total Operating Income		 -96 -85 -60
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 96 85 60
Selling, General & Admin Expense		 23 20 18
Research & Development Expense		 73 65 42
Total Other Income / (Expense), net		 9.31 8.72 1.53
Interest Expense		 -9.43 -8.59 -1.86
Other Income / (Expense), net		 -0.12 0.13 -0.33
Income Tax Expense		 0.11 0.14 0.00
Basic Earnings per Share		 ($1.75) ($1.93) ($1.96)
Weighted Average Basic Shares Outstanding		 49.65M 39.62M 29.94M
Diluted Earnings per Share		 ($1.75) ($1.93) ($1.96)
Weighted Average Diluted Shares Outstanding		 49.65M 39.62M 29.94M
Weighted Average Basic & Diluted Shares Outstanding		 50.23M 49.50M 37.80M

Quarterly Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -26 -21 -20 -20 -22 -19 -18 -17 -17 -16
Consolidated Net Income / (Loss)		 -26 -21 -20 -20 -22 -19 -18 -17 -17 -16
Net Income / (Loss) Continuing Operations		 -26 -21 -20 -20 -22 -19 -18 -17 -17 -16
Total Pre-Tax Income 		-26 -21 -20 -20 -22 -19 -18 -17 -17 -16
Total Operating Income		 -28 -23 -23 -22 -25 -20 -20 -19 -18 -16
Total Operating Expenses		 28 23 23 22 25 20 20 19 18 16
Selling, General & Admin Expense		 5.47 6.20 5.88 5.26 4.50 5.06 5.16 5.04 4.45 4.76
Research & Development Expense		 22 17 17 17 20 15 15 14 13 11
Total Other Income / (Expense), net		 2.00 2.23 2.43 2.65 2.79 1.98 1.98 1.98 1.05 0.15
Interest Expense		 -2.04 -2.26 -2.45 -2.69 -2.61 -1.98 -2.01 -1.99 -1.06 -0.48
Other Income / (Expense), net		 -0.04 -0.03 -0.03 -0.03 0.18 -0.01 -0.03 -0.01 -0.01 -0.33
Income Tax Expense		 0.02 0.04 0.00 0.05 0.14 0.00 0.00 0.00 - -
Basic Earnings per Share		 ($0.52) ($0.42) ($0.41) ($0.40) ($0.51) ($0.48) ($0.48) ($0.46) ($0.52) ($0.54)
Weighted Average Basic Shares Outstanding		 49.65M 49.66M 49.55M 49.45M 39.62M 38.19M 37.86M 37.78M 29.94M 29.27M
Diluted Earnings per Share		 ($0.52) ($0.42) ($0.41) ($0.40) ($0.51) ($0.48) ($0.48) ($0.46) ($0.52) ($0.54)
Weighted Average Diluted Shares Outstanding		 49.65M 49.66M 49.55M 49.45M 39.62M 38.19M 37.86M 37.78M 29.94M 29.27M
Weighted Average Basic & Diluted Shares Outstanding		 50.23M 49.95M 49.61M 49.54M 49.50M 38.26M 38.20M 37.80M 37.80M 29.33M

Annual Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 -9.39 -81 -27
Net Cash From Operating Activities		 -80 -64 -55
Net Cash From Continuing Operating Activities		 -80 -64 -55
Net Income / (Loss) Continuing Operations		 -87 -76 -59
Consolidated Net Income / (Loss)		 -87 -76 -59
Depreciation Expense		 1.22 1.30 1.18
Non-Cash Adjustments To Reconcile Net Income		 8.54 6.83 6.09
Changes in Operating Assets and Liabilities, net		 -2.65 4.44 -3.10
Net Cash From Investing Activities		 69 -114 -68
Net Cash From Continuing Investing Activities		 69 -114 -68
Purchase of Property, Plant & Equipment		 -1.25 -0.71 -1.09
Purchase of Investments		 -59 -234 -120
Sale and/or Maturity of Investments		 129 120 53
Net Cash From Financing Activities		 1.60 97 96
Net Cash From Continuing Financing Activities		 1.60 97 96
Issuance of Common Equity		 0.18 96 95
Other Financing Activities, net		 1.42 1.38 0.43

Quarterly Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 6.29 -4.67 3.80 -15 -15 7.85 9.24 -83 60 7.29
Net Cash From Operating Activities		 -24 -15 -16 -24 -17 -15 -15 -16 -18 -11
Net Cash From Continuing Operating Activities		 -24 -15 -16 -24 -17 -15 -15 -16 -17 -11
Net Income / (Loss) Continuing Operations		 -26 -21 -20 -20 -22 -19 -18 -17 -17 -16
Consolidated Net Income / (Loss)		 -26 -21 -20 -20 -22 -19 -18 -17 -17 -16
Depreciation Expense		 0.29 0.31 0.31 0.31 0.32 0.34 0.30 0.33 0.32 0.30
Non-Cash Adjustments To Reconcile Net Income		 2.53 2.08 2.41 1.52 2.39 2.20 1.21 1.02 1.20 1.72
Changes in Operating Assets and Liabilities, net		 -0.94 3.38 1.49 -6.57 2.03 0.81 1.89 -0.30 -2.45 2.46
Net Cash From Investing Activities		 30 9.89 20 9.40 -90 22 21 -67 -17 18
Net Cash From Continuing Investing Activities		 30 9.89 20 9.27 -90 22 21 -67 -17 18
Purchase of Property, Plant & Equipment		 -0.30 -0.34 -0.40 -0.21 -0.32 -0.09 -0.18 -0.12 -0.36 -0.06
Sale and/or Maturity of Investments		 30 30 30 39 55 22 22 22 32 18
Net Cash From Financing Activities		 0.54 0.72 0.08 0.25 93 1.63 2.48 0.20 95 0.10
Net Cash From Continuing Financing Activities		 0.54 0.72 0.08 0.25 93 1.63 2.48 0.20 95 0.10
Other Financing Activities, net		 0.54 0.63 0.08 0.16 0.37 0.20 0.66 0.15 - 0.10

Annual Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 183 255 224
Total Current Assets		 161 232 197
Cash & Equivalents		 32 41 122
Restricted Cash		 0.00 0.02 0.02
Short-Term Investments		 119 185 67
Prepaid Expenses		 9.53 5.63 7.87
Plant, Property, & Equipment, net		 3.22 3.15 5.37
Total Noncurrent Assets		 19 20 22
Other Noncurrent Operating Assets		 18 19 21
Other Noncurrent Nonoperating Assets		 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 183 255 224
Total Liabilities		 31 29 28
Total Current Liabilities		 15 12 10
Accounts Payable		 2.30 1.79 2.92
Accrued Expenses		 9.46 7.88 4.57
Other Current Liabilities		 3.15 2.69 2.96
Total Noncurrent Liabilities		 16 17 18
Other Noncurrent Operating Liabilities		 16 17 18
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 152 226 196
Total Preferred & Common Equity		 152 226 196
Total Common Equity		 152 226 196
Common Stock		 526 513 407
Retained Earnings		 -374 -287 -211
Accumulated Other Comprehensive Income / (Loss)		 0.26 0.54 -0.07

Quarterly Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 205 218 235 180 193 206 143
Total Current Assets		 183 196 212 154 166 179 116
Cash & Equivalents		 25 30 26 56 48 38 61
Restricted Cash		 0.00 0.00 0.00 0.02 0.02 0.02 0.18
Short-Term Investments		 149 157 177 93 114 135 50
Prepaid Expenses		 9.10 8.18 9.38 4.81 4.18 5.58 4.21
Plant, Property, & Equipment, net		 3.33 3.33 3.05 4.86 5.06 5.17 5.48
Total Noncurrent Assets		 19 19 20 21 21 22 22
Other Noncurrent Operating Assets		 18 19 19 20 21 21 21
Other Noncurrent Nonoperating Assets		 0.77 0.77 0.77 0.77 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 205 218 235 180 193 206 143
Total Liabilities		 31 27 26 28 26 26 28
Total Current Liabilities		 15 11 9.66 11 8.90 8.11 9.96
Accounts Payable		 1.99 1.46 1.93 1.49 0.55 1.06 1.72
Accrued Expenses		 9.60 6.34 4.99 6.37 5.33 4.07 5.30
Other Current Liabilities		 3.13 2.75 2.74 3.04 3.01 2.99 2.94
Total Noncurrent Liabilities		 16 16 17 17 17 18 18
Other Noncurrent Operating Liabilities		 16 16 17 17 17 18 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 175 191 209 152 166 180 115
Total Preferred & Common Equity		 175 191 209 152 166 180 115
Total Common Equity		 175 191 209 152 166 180 115
Common Stock		 522 519 516 417 413 409 310
Retained Earnings		 -348 -327 -307 -265 -247 -228 -194
Accumulated Other Comprehensive Income / (Loss)		 0.61 -0.18 0.02 -0.13 -0.22 -0.05 -0.15

Annual Metrics And Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -13.70% -40.56% -72.71%
EBIT Growth		 -13.41% -39.97% -71.98%
NOPAT Growth		 -13.09% -40.96% -71.05%
Net Income Growth		 -13.76% -30.03% -66.70%
EPS Growth		 9.33% 1.53% 78.10%
Operating Cash Flow Growth		 -24.99% -16.93% -68.47%
Free Cash Flow Firm Growth		 -30.63% -16.27% -74.06%
Invested Capital Growth		 109.92% -118.20% 92.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -3.57% -9.11% -24.84%
EBIT Q/Q Growth		 -3.49% -8.96% -24.48%
NOPAT Q/Q Growth		 -3.25% -9.21% -24.63%
Net Income Q/Q Growth		 -4.45% -7.87% -9.15%
EPS Q/Q Growth		 -0.57% 0.52% -102.92%
Operating Cash Flow Q/Q Growth		 -8.96% 0.97% -12.18%
Free Cash Flow Firm Q/Q Growth		 -9.02% 2.50% 0.00%
Invested Capital Q/Q Growth		 122.64% -158.11% 131.49%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.13% 100.18% 100.00%
Interest Burden Percent		 90.20% 89.88% 96.93%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.01% -36.26% -33.78%
Cash Return on Invested Capital (CROIC)		 -63,405.74% 0.00% -992.22%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -46.01% -36.26% -33.78%
Return on Equity Simple (ROE_SIMPLE)		 -57.19% -33.83% -30.05%
Net Operating Profit after Tax (NOPAT)		 -67 -59 -42
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -10.37% -8.12% -9.77%
Return On Investment Capital (ROIC_SIMPLE)		 -44.27% -26.34% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -96 -85 -61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -95 -84 -59
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 2.70 1.50 1.57
Price to Tangible Book Value (P/TBV)		 2.70 1.50 1.57
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2,402.84 0.00 19.92
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.00 -0.99 -0.97
Leverage Ratio		 1.16 1.14 1.10
Compound Leverage Factor		 1.04 1.02 1.07
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 4.42 5.32 5.30
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 10.77 18.76 18.81
Quick Ratio		 10.13 18.30 18.06
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -68 -52 -45
Operating Cash Flow to CapEx		 -6,369.11% -9,005.22% -4,990.95%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 0.11 -1.09 5.98
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.20 -7.07 2.88
Enterprise Value (EV)		 260 113 119
Market Capitalization		 411 339 308
Book Value per Share		 $3.04 $5.90 $6.67
Tangible Book Value per Share		 $3.04 $5.90 $6.67
Total Capital		 152 226 196
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -151 -226 -189
Capital Expenditures (CapEx)		 1.25 0.71 1.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.38 -6.73 -2.59
Debt-free Net Working Capital (DFNWC)		 146 219 186
Net Working Capital (NWC)		 146 219 186
Net Nonoperating Expense (NNE)		 20 17 17
Net Nonoperating Obligations (NNO)		 -152 -227 -190
Total Depreciation and Amortization (D&A)		 1.22 1.30 1.18
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($1.75) ($1.93) ($1.96)
Adjusted Weighted Average Basic Shares Outstanding		 49.65M 39.62M 29.94M
Adjusted Diluted Earnings per Share		 ($1.75) ($1.93) ($1.96)
Adjusted Weighted Average Diluted Shares Outstanding		 49.65M 39.62M 29.94M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.23M 49.50M 37.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -67 -59 -42
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -13.50% -13.87% -12.33% -15.21% -40.33% -25.30% -48.60% -51.77% -216.21% -86.41%
EBIT Growth		 -13.19% -13.49% -12.21% -14.84% -39.60% -25.08% -47.59% -51.30% -209.12% -85.28%
NOPAT Growth		 -12.21% -13.39% -12.26% -14.76% -40.71% -27.61% -46.76% -51.78% -209.16% -80.49%
Net Income Growth		 -16.73% -13.67% -11.14% -12.82% -33.65% -16.42% -35.87% -36.08% -42.33% -79.92%
EPS Growth		 -1.96% 12.50% 14.58% 13.04% 1.92% 11.11% -4.35% -4.55% -100.76% 98.09%
Operating Cash Flow Growth		 -37.76% 0.84% -10.13% -48.99% 3.48% -43.15% -37.80% -7.97% -49.04% -23.82%
Free Cash Flow Firm Growth		 -101.10% -2.06% -32.04% -24.45% 32.44% -18.44% 24.95% 28.41% 0.00% -34.74%
Invested Capital Growth		 109.92% -125.45% -10.07% -13.57% -118.20% -27.50% -39.79% -22.32% 92.78% 11.66%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -20.10% -2.09% -1.98% 9.22% -20.48% -0.71% -4.60% -10.57% -7.57% -19.44%
EBIT Q/Q Growth		 -19.73% -2.06% -1.98% 9.17% -20.05% -0.91% -4.37% -10.41% -7.56% -19.07%
NOPAT Q/Q Growth		 -19.70% -2.06% -2.01% 9.97% -20.96% -1.05% -4.28% -10.40% -9.70% -16.21%
Net Income Q/Q Growth		 -22.77% -3.47% -3.20% 10.96% -19.55% -1.16% -4.77% -5.48% -4.14% -18.07%
EPS Q/Q Growth		 -23.81% -2.44% -2.50% 21.57% -6.25% 0.00% -4.35% 11.54% 3.70% -17.39%
Operating Cash Flow Q/Q Growth		 -56.83% 5.30% 34.04% -40.63% -12.88% -5.18% 10.77% 8.89% -67.41% -1.24%
Free Cash Flow Firm Q/Q Growth		 -48.54% 10.64% -5.10% -44.16% 24.62% -15.61% 0.94% 21.75% -32.16% 26.75%
Invested Capital Q/Q Growth		 122.64% -114.59% -36.39% 572.08% -158.11% -48.46% -38.87% -0.60% 131.49% -57.19%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.09% 100.20% 100.00% 100.23% 100.62% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 92.69% 90.29% 89.24% 87.98% 89.40% 90.33% 90.11% 89.77% 93.96% 97.05%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.01% -50.99% -45.09% -40.43% -36.26% -53.11% -46.17% -39.46% -33.78% -54.02%
Cash Return on Invested Capital (CROIC)		 -63,405.74% 0.00% -1,820.92% -1,094.69% 0.00% -2,411.47% -1,012.27% -663.59% -992.22% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -46.01% -50.99% -45.09% -40.43% -36.26% -53.11% -46.17% -39.46% -33.78% 4.32%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -47.64% -42.14% -37.67% 0.00% -46.69% -40.99% -35.17% 0.00% -46.79%
Net Operating Profit after Tax (NOPAT)		 -19 -16 -16 -16 -17 -14 -14 -14 -12 -11
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.36% -2.94% -2.51% -2.16% -2.30% -3.18% -2.87% -2.51% -2.50% -4.80%
Return On Investment Capital (ROIC_SIMPLE)		 -12.81% - - - -7.68% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -28 -23 -23 -22 -25 -20 -20 -19 -18 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -23 -22 -22 -24 -20 -20 -19 -17 -16
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.70 2.53 1.96 1.86 1.50 2.26 2.80 1.95 1.57 4.61
Price to Tangible Book Value (P/TBV)		 2.70 2.53 1.96 1.86 1.50 2.26 2.80 1.95 1.57 4.61
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2,402.84 0.00 57.23 36.13 0.00 103.28 83.83 29.80 19.92 161.99
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.00 -0.98 -0.97 -0.99 -0.98 -0.97 -0.96 -0.97 -0.98
Leverage Ratio		 1.16 1.18 1.15 1.13 1.14 1.21 1.11 1.10 1.10 1.17
Compound Leverage Factor		 1.07 1.07 1.02 1.00 1.02 1.09 1.00 0.98 1.04 1.14
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.65 6.88 6.95 7.78 6.10 5.84 9.49 7.30 5.94 9.94
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 108.01%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 10.77 12.47 18.54 21.97 18.76 14.13 18.69 22.09 18.81 11.63
Quick Ratio		 10.13 11.85 17.77 20.99 18.30 13.68 18.21 21.40 18.06 11.19
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -21 -14 -16 -15 -10 -14 -12 -12 -15 -12
Operating Cash Flow to CapEx		 -8,010.70% -4,478.89% -4,001.99% -11,643.81% -5,484.86% -17,114.44% -8,227.53% -13,235.48% -5,031.56% -17,079.37%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.11 -0.48 3.27 5.14 -1.09 1.87 3.64 5.95 5.98 2.59
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.20 -2.35 -0.37 -0.81 -7.07 -0.71 -2.40 -1.71 2.88 0.27
Enterprise Value (EV)		 260 268 187 186 113 194 305 177 119 419
Market Capitalization		 411 442 375 389 339 343 467 351 308 530
Book Value per Share		 $3.04 $3.52 $3.86 $4.22 $5.90 $3.97 $4.40 $4.77 $6.67 $3.93
Tangible Book Value per Share		 $3.04 $3.52 $3.86 $4.22 $5.90 $3.97 $4.40 $4.77 $6.67 $3.93
Total Capital		 152 175 191 209 226 152 166 180 196 115
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -151 -174 -187 -203 -226 -149 -162 -174 -189 -112
Capital Expenditures (CapEx)		 0.30 0.34 0.40 0.21 0.32 0.09 0.18 0.12 0.36 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.38 -5.61 -2.37 -0.29 -6.73 -6.08 -4.72 -2.53 -2.59 -5.76
Debt-free Net Working Capital (DFNWC)		 146 169 185 203 219 143 157 171 186 106
Net Working Capital (NWC)		 146 169 185 203 219 143 157 171 186 106
Net Nonoperating Expense (NNE)		 6.37 4.78 4.40 4.09 4.78 4.17 4.11 3.86 4.23 4.66
Net Nonoperating Obligations (NNO)		 -152 -175 -188 -204 -227 -150 -163 -174 -190 -112
Total Depreciation and Amortization (D&A)		 0.29 0.31 0.31 0.31 0.32 0.34 0.30 0.33 0.32 0.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.52) ($0.42) ($0.41) ($0.40) ($0.51) ($0.48) ($0.48) ($0.46) ($0.52) ($0.54)
Adjusted Weighted Average Basic Shares Outstanding		 49.65M 49.66M 49.55M 49.45M 39.62M 38.19M 37.86M 37.78M 29.94M 29.27M
Adjusted Diluted Earnings per Share		 ($0.52) ($0.42) ($0.41) ($0.40) ($0.51) ($0.48) ($0.48) ($0.46) ($0.52) ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 49.65M 49.66M 49.55M 49.45M 39.62M 38.19M 37.86M 37.78M 29.94M 29.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.23M 49.95M 49.61M 49.54M 49.50M 38.26M 38.20M 37.80M 37.80M 29.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -16 -16 -16 -17 -14 -14 -14 -12 -11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Aura Biosciences' Financials

When does Aura Biosciences's fiscal year end?

According to the most recent income statement we have on file, Aura Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Aura Biosciences' net income changed over the last 2 years?

Aura Biosciences' net income appears to be on an upward trend, with a most recent value of -$86.92 million in 2024, rising from -$58.76 million in 2022. The previous period was -$76.41 million in 2023. View Aura Biosciences' forecast to see where analysts expect Aura Biosciences to go next.

What is Aura Biosciences's operating income?
Aura Biosciences's total operating income in 2024 was -$96.12 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $96.12 million
How has Aura Biosciences revenue changed over the last 2 years?

Over the last 2 years, Aura Biosciences' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Aura Biosciences have?

Aura Biosciences' total liabilities were at $30.53 million at the end of 2024, a 4.5% increase from 2023, and a 7.7% increase since 2022.

How much cash does Aura Biosciences have?

In the past 2 years, Aura Biosciences' cash and equivalents has ranged from $31.69 million in 2024 to $121.58 million in 2022, and is currently $31.69 million as of their latest financial filing in 2024.

How has Aura Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Aura Biosciences' book value per share changed from 6.67 in 2022 to 3.04 in 2024, a change of -54.4%.


Related Companies

This page (NASDAQ:AURA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Take a look at this picture ...
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...
Weiss Ratings | Sponsored
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored